8-K: DURECT Corp Announces Q3 2024 Results and Plans Phase 3 Trial for Larsucosterol

DURECT Corporation reported its third quarter 2024 financial results and provided an update on its business, including plans to initiate a Phase 3 trial for larsucosterol.

Summary

• DURECT Corporation announced its third quarter 2024 financial results, with total revenues of $1.9 million and a net loss of $4.3 million.
• The company is focused on initiating a Phase 3 trial for larsucosterol in severe alcohol-associated hepatitis (AH), with topline results expected within two years of trial initiation.
• The FDA has agreed that a single successful Phase 3 trial may be sufficient for a New Drug Application (NDA).
• The primary endpoint of the Phase 3 trial will be 90-day survival, which is considered clinically meaningful.
• DURECT plans to present additional data from the Phase 2b AHFIRM trial at The Liver Meeting 2024.
• Innocoll Pharmaceuticals is terminating its license agreement for POSIMIR, effective May 2025, and DURECT is evaluating next steps for commercialization.
• Cash, cash equivalents, and investments totaled $10.5 million at September 30, 2024, compared to $29.8 million at December 31, 2023.
• Debt was $10.5 million at September 30, 2024, compared to $16.7 million at December 31, 2023.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the progress on larsucosterol and the potential for a single Phase 3 trial are positive, the increased net loss, decreased cash reserves, and the termination of the POSIMIR license agreement are concerning. The need for additional funding also adds uncertainty.

Positives

• The FDA has agreed that a single successful Phase 3 trial may be sufficient for NDA approval of larsucosterol.
• The primary endpoint of 90-day survival is considered clinically meaningful and has a high probability of success based on Phase 2b data.
• DURECT is actively engaging with clinical sites and hepatologists to streamline the Phase 3 trial initiation.
• Larsucosterol has received Fast Track and Breakthrough Therapy designations from the FDA.
• DURECT is presenting additional data from the Phase 2b AHFIRM trial at a major liver conference.
• The company has reduced its debt from $16.7 million at the end of 2023 to $10.5 million at the end of Q3 2024.

Negatives

• DURECT reported a net loss of $4.3 million for Q3 2024, an increase from the $3.0 million loss in Q3 2023.
• Cash, cash equivalents, and investments decreased significantly from $29.8 million at the end of 2023 to $10.5 million at the end of Q3 2024.
• Innocoll Pharmaceuticals is terminating its license agreement for POSIMIR, which may impact future revenue.
• The company needs to secure sufficient funding to initiate the Phase 3 trial for larsucosterol.

Risks

• The company's ability to commence the Phase 3 trial is subject to obtaining sufficient funding.
• There is a risk that the Phase 3 trial may not confirm the results from the Phase 2b trial.
• The FDA may require additional clinical trials before approving larsucosterol.
• The company faces risks related to its cash resources and ability to continue as a going concern.
• The termination of the POSIMIR license agreement could negatively impact revenue.

Future Outlook

DURECT aims to initiate the Phase 3 trial for larsucosterol as soon as possible, subject to funding, and expects topline data within two years of trial initiation. The company is also evaluating options for the commercialization of POSIMIR after the termination of the license agreement.

Management Comments

• James E. Brown, D.V.M., President and CEO of DURECT, stated that the company remains focused on preparations for the Phase 3 trial for larsucosterol.
• Management believes the selected primary endpoint of 90-day survival provides the greatest probability of success based on the Phase 2b AHFIRM data.
• Management believes that larsucosterol, if approved, could significantly improve the current 90-day mortality rates of approximately 30% for AH.

Industry Context

The announcement is relevant to the biopharmaceutical industry, particularly companies focused on developing treatments for liver diseases. The focus on epigenetic therapies and the potential for larsucosterol to address a significant unmet need in alcohol-associated hepatitis positions DURECT as a key player in this space. The termination of the POSIMIR license agreement highlights the challenges of commercializing pharmaceutical products and the importance of strategic partnerships.

Comparison to Industry Standards

• The 90-day mortality rate of approximately 30% in severe alcohol-associated hepatitis (AH) is consistent with industry data, highlighting the need for effective treatments.
• The Phase 3 trial design, incorporating feedback from the FDA and learnings from the Phase 2b AHFIRM trial, aligns with industry best practices for clinical trial development.
• The use of 90-day survival as the primary endpoint is a common metric in AH clinical trials, making the results comparable to other studies.
• Companies like Intercept Pharmaceuticals and Genfit have also been developing treatments for liver diseases, but DURECT's focus on epigenetic modulation with larsucosterol is a unique approach.
• The termination of the POSIMIR license agreement is not uncommon in the pharmaceutical industry, where companies often re-evaluate their product portfolios and partnerships.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and decreased cash reserves.
• Employees may be impacted by the company's financial situation and the need for additional funding.
• Patients with severe alcohol-associated hepatitis may benefit from the development of larsucosterol.
• The termination of the POSIMIR license agreement may impact suppliers and partners.

Next Steps

• DURECT plans to initiate the Phase 3 trial for larsucosterol.
• The company will present additional data from the Phase 2b AHFIRM trial at The Liver Meeting 2024.
• DURECT is evaluating next steps for the commercialization of POSIMIR.
• The company will host a conference call and webcast to discuss the Q3 2024 results.

Key Dates

Keywords

larsucosterol, alcohol-associated hepatitis, Phase 3 trial, AH, FDA, clinical trial, epigenetic, POSIMIR, DURECT, financial results